Micreos BV

The once-shocking $100m-plus venture capital round is not such a shock anymore in the biopharmaceutical sector, since the number of mega-rounds has increased over the last few years as drug developmen

Exo Therapeutics, Inc. launched in December with $25m in series A venture capital and has advanced its ExoSight technology platform far enough since then to justify a $78m series B round that the com

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmace

The 2011 start-up Arteaus Therapeutics LLC , funded by Atlas Venture and OrbiMed, has generated a return more than 16 times the original $18m the venture capital firms invested in the company now tha